The chronic administration of the highest dose of bezafibrate to rats was associated with hepatic tumour formation in females. This dose was in the order of 30-40 times the human dose. No such adverse effect was apparent at reduced intake levels approximating more closely to the lipid-lowering dosage in humans.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign Out
